velnacrine has been researched along with Alzheimer Disease in 31 studies
velnacrine: RN given refers to (+-)-isomer; RN for cpd without isomeric designation not available 8/88; structure in first source; potential Alzheimer's disease drug but trial halted due to abnormal liver tests
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the long-term effectiveness and safety of an investigational cholinesterase inhibitor, that is, velnacrine maleate, in treating patients with clinically probable Alzheimer's disease (according to the criteria of the National Institute of Neurological Disorders and Stroke [Washington, DC]-Alzheimer Disease and Related Disorders Association [Chicago, Ill])." | 5.08 | Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group. ( Antuono, PG, 1995) |
| "Patients with Alzheimer's disease received 150 mg/day and 225 mg/day Velnacrine maleate (parallel-group treatment) and placebo." | 2.68 | Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease. ( Clipp, EC; Moore, MJ, 1995) |
| "4) Velnacrine was shown to bind to both albumin and alpha 1-acid glycoprotein, but together they did not account for total binding." | 2.68 | Variability in the plasma protein binding of velnacrine (1-hydroxy tacrine hydrochloride). A potential agent for Alzheimer's disease. ( Ford, JM; Roberts, CJ; Wood, DM, 1996) |
| " Direct liver injury, possibly associated with the production of a toxic metabolite, would be consistent with reports of aberrant xenobiotic metabolism in Alzheimer's disease patients." | 2.67 | Clinical trials with velnacrine: (PROPP) the physician reference of predicted probabilities--a statistical model for the estimation of hepatotoxicity risk with velnacrine maleate. ( Hardiman, S; Miller, K; Murphy, M, 1993) |
| "Velnacrine was administered in various doses." | 2.67 | Implications of the study population in the early evaluation of anticholinesterase inhibitors for Alzheimer's disease. ( Cutler, NR; Murphy, MF; Nash, RJ; Sramek, JJ, 1992) |
| "Velnacrine was rapidly absorbed after oral administration." | 2.67 | Multiple dose pharmacokinetics, safety, and tolerance of velnacrine (HP 029) in healthy elderly subjects: a potential therapeutic agent for Alzheimer's disease. ( Ho, I; Hsu, R; Lassman, HB; Puri, SK, 1990) |
| " To assess adverse events in relation to dosage and plasma drug levels, 24 hospitalized AD subjects were randomly assigned to receive placebo or HP 029 for 10 days in a double-blind, sequential escalation study." | 2.67 | Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings. ( Cutler, NR; De Luna, DM; Murphy, MF; Nash, RJ; Prior, PL, 1990) |
| " In this open, randomized, crossover study, 24 healthy, elderly men were given 100 mg of velnacrine on two different study days to assess the influence of food on the bioavailability of velnacrine." | 2.66 | The effect of food on the bioavailability of velnacrine (HP 029) in healthy elderly men: a potential Alzheimer agent. ( Ho, I; Hsu, RS; Lassman, HB; Puri, SK, 1989) |
| " The mean plasma half-life was about 2." | 2.66 | Single dose safety, tolerance, and pharmacokinetics of HP 029 in healthy young men: a potential Alzheimer agent. ( Ho, I; Hsu, RS; Lassman, HB; Puri, SK, 1989) |
| "Velnacrine is a derivative of tacrine." | 2.42 | Velnacrine for Alzheimer's disease. ( Birks, J; Wilcock, GG, 2004) |
| " The two drugs are special as the dosage of them is guided mainly by side effects and not by therapeutic effects in contrast to most drugs used for psychiatric disorders." | 2.38 | Side effects of long acting cholinesterase inhibitors. ( Beermann, B, 1993) |
| "Velnacrine maleate is a novel, orally active acetylcholinesterase inhibitor of the acridine class with a longer duration of action than physostigmine." | 1.29 | Velnacrine maleate improves delayed matching performance by aged monkeys. ( Buccafusco, JJ; Jackson, WJ; Rush, DK; Terry, AV; Turk, DJ, 1995) |
| "The acridine-based, potential Alzheimer's disease therapeutic agents, tacrine and velnacrine, were incubated with rat or gerbil neocortical synaptosomal membranes." | 1.29 | Interaction of tacrine and velnacrine with neocortical synaptosomal membranes: relevance to Alzheimer's disease. ( Butterfield, DA; Carney, J; Hall, N; Hensley, K; Umhauer, S, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (12.90) | 18.7374 |
| 1990's | 24 (77.42) | 18.2507 |
| 2000's | 3 (9.68) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shutske, GM | 2 |
| Pierrat, FA | 2 |
| Kapples, KJ | 1 |
| Cornfeldt, ML | 2 |
| Szewczak, MR | 2 |
| Huger, FP | 2 |
| Bores, GM | 2 |
| Haroutunian, V | 2 |
| Davis, KL | 2 |
| Birks, J | 1 |
| Wilcock, GG | 1 |
| Silva, AS | 1 |
| Saldanha, C | 1 |
| Martins e Silva, J | 1 |
| Jackson, WJ | 1 |
| Buccafusco, JJ | 1 |
| Terry, AV | 1 |
| Turk, DJ | 1 |
| Rush, DK | 1 |
| Clipp, EC | 2 |
| Moore, MJ | 2 |
| Antuono, PG | 1 |
| al Casey, S | 1 |
| Brewster, D | 1 |
| Viau, C | 1 |
| Acosta, D | 1 |
| Schehr, RS | 1 |
| Siegfried, KR | 1 |
| Hardiman, S | 1 |
| Miller, K | 1 |
| Murphy, M | 2 |
| Beermann, B | 1 |
| Butterfield, DA | 2 |
| Hensley, K | 1 |
| Hall, N | 1 |
| Umhauer, S | 1 |
| Carney, J | 1 |
| Cutler, NR | 4 |
| Sramek, JJ | 3 |
| Zemlan, FP | 2 |
| Keys, M | 1 |
| Richter, RW | 1 |
| Strub, RL | 1 |
| Pomara, N | 2 |
| Citrome, L | 1 |
| Wood, DM | 1 |
| Ford, JM | 1 |
| Roberts, CJ | 1 |
| Tabarrini, O | 1 |
| Cecchetti, V | 1 |
| Temperini, A | 1 |
| Filipponi, E | 1 |
| Lamperti, MG | 1 |
| Fravolini, A | 1 |
| Rangachari, A | 1 |
| Ebmeier, KP | 1 |
| Hunter, R | 1 |
| Curran, SM | 1 |
| Dougal, NJ | 1 |
| Murray, CL | 1 |
| Wyper, DJ | 1 |
| Patterson, J | 1 |
| Hanson, MT | 1 |
| Siegfried, K | 2 |
| Goodwin, GM | 1 |
| Murphy, MF | 3 |
| Nash, RJ | 3 |
| Deptula, D | 1 |
| Singh, R | 1 |
| Hardiman, ST | 1 |
| Huff, FJ | 1 |
| Demkovich, JJ | 1 |
| Dobson, C | 1 |
| Knappe, UE | 1 |
| Wesnes, KA | 1 |
| Simpson, PM | 1 |
| White, L | 1 |
| Pinker, S | 1 |
| Jertz, G | 1 |
| Puri, SK | 3 |
| Ho, I | 3 |
| Hsu, R | 1 |
| Lassman, HB | 3 |
| Prior, PL | 1 |
| De Luna, DM | 1 |
| Hsu, RS | 2 |
3 reviews available for velnacrine and Alzheimer Disease
| Article | Year |
|---|---|
Velnacrine for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Randomized Controlled Trials as Topic; Tacrine | 2004 |
Pharmacodynamic and early clinical studies with velnacrine.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Female; Huma | 1993 |
Side effects of long acting cholinesterase inhibitors.
Topics: Alzheimer Disease; Chemical and Drug Induced Liver Injury; Cholinesterase Inhibitors; Clinical Trial | 1993 |
17 trials available for velnacrine and Alzheimer Disease
| Article | Year |
|---|---|
Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cognition; Double-Blind Method; Female; Huma | 1995 |
Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Double-Blin | 1995 |
Alzheimer's disease and caregiver time.
Topics: Activities of Daily Living; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Double-Blind M | 1994 |
Pharmacodynamic and early clinical studies with velnacrine.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Female; Huma | 1993 |
Clinical trials with velnacrine: (PROPP) the physician reference of predicted probabilities--a statistical model for the estimation of hepatotoxicity risk with velnacrine maleate.
Topics: Age Factors; Aged; Alzheimer Disease; Chemical and Drug Induced Liver Injury; Cholinesterase Inhibit | 1993 |
The target population in phase I clinical trials of cholinergic compounds in Alzheimer disease: the role of the "bridging study".
Topics: Alzheimer Disease; Cholinergic Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; | 1995 |
Double-blind placebo-controlled study of velnacrine in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, D | 1996 |
Variability in the plasma protein binding of velnacrine (1-hydroxy tacrine hydrochloride). A potential agent for Alzheimer's disease.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aging; Alzheimer Disease; Binding, Compet | 1996 |
Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; D | 1996 |
Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cerebrovascular Circulation; Cholinesterase Inhibitors; Cognition; Double-B | 1992 |
Implications of the study population in the early evaluation of anticholinesterase inhibitors for Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Method; Drug Adm | 1992 |
Pretreatment postural blood pressure drop as a possible predictor of response to the cholinesterase inhibitor velnacrine (HP 029) in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Method; Female; Humans; Hypotension | 1991 |
Evaluation of HP 029 (velnacrine maleate) in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Drug Evaluation; Female; Humans; Male; Middle Ag | 1991 |
Multiple dose pharmacokinetics, safety, and tolerance of velnacrine (HP 029) in healthy elderly subjects: a potential therapeutic agent for Alzheimer's disease.
Topics: Administration, Oral; Aged; Alzheimer Disease; Drug Administration Schedule; Drug Evaluation; Half-L | 1990 |
Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Aminoacridines; Double-Blind Metho | 1990 |
The effect of food on the bioavailability of velnacrine (HP 029) in healthy elderly men: a potential Alzheimer agent.
Topics: Aged; Alzheimer Disease; Aminoacridines; Biological Availability; Chromatography, High Pressure Liqu | 1989 |
Single dose safety, tolerance, and pharmacokinetics of HP 029 in healthy young men: a potential Alzheimer agent.
Topics: Adult; Alzheimer Disease; Aminoacridines; Double-Blind Method; Drug Evaluation; Drug Tolerance; Huma | 1989 |
12 other studies available for velnacrine and Alzheimer Disease
| Article | Year |
|---|---|
9-Amino-1,2,3,4-tetrahydroacridin-1-ols: synthesis and evaluation as potential Alzheimer's disease therapeutics.
Topics: Alzheimer Disease; Aminoacridines; Animals; Chemical Phenomena; Chemistry; Cholinesterase Inhibitors | 1989 |
Effects of velnacrine maleate in the leukocyte-endothelial cell interactions in rat cremaster microcirculatory network.
Topics: Acetylcholine; Alzheimer Disease; Animals; Blood Pressure; Cholinesterase Inhibitors; Endothelium, V | 2007 |
Velnacrine maleate improves delayed matching performance by aged monkeys.
Topics: Aging; Alzheimer Disease; Animals; Behavior, Animal; Cholinesterase Inhibitors; Dose-Response Relati | 1995 |
Effect of glutathione depletion and oxidative stress on the in vitro cytotoxicity of velnacrine maleate.
Topics: Alzheimer Disease; Animals; Cells, Cultured; Cholinesterase Inhibitors; Fluorescent Dyes; Formazans; | 1995 |
Therapeutic approaches to Alzheimer's disease. An informal survey of promising drug discovery strategies.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Drug Design; Humans; Neurotrans | 1994 |
Interaction of tacrine and velnacrine with neocortical synaptosomal membranes: relevance to Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cerebral Cortex; Cholinesterase Inhibitors; Cytoskeletal Proteins; Elect | 1993 |
Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dihydropyridines; Ethics, Me | 1995 |
Transient elevations in pancreatic enzymes in response to a cholinesterase inhibitor.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Male; Middle Aged; Pancreas; Tacrine | 1995 |
Velnacrine thiaanalogues as potential agents for treating Alzheimer's disease.
Topics: Administration, Oral; Alzheimer Disease; Animals; Avoidance Learning; Blood Cells; Chlorine; Choline | 2001 |
Membrane-altering effects of velnacrine and N-methylacridinium: relevance to tacrine and Alzheimer's disease.
Topics: Acridines; Alzheimer Disease; Cytoskeletal Proteins; Cytoskeleton; Electron Spin Resonance Spectrosc | 1992 |
Cholinesterase inhibition in the scopolamine model of dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Memory; Scopolamine; Tacrine | 1991 |
(+/-)-9-Amino-1,2,3,4-tetrahydroacridin-1-ol. A potential Alzheimer's disease therapeutic of low toxicity.
Topics: Alzheimer Disease; Aminoacridines; Animals; Chemical and Drug Induced Liver Injury; Chemical Phenome | 1988 |